Physician profile
Roberto Rupcich
NPI 1811342645
$349.00
in general payments reported to CMS, 2019-2025
11 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.02 · 2020: $129 · 2024: $63.65 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $163.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76.90 | 2020-2024 | Wegovy |
| Pfizer INC. | $68.26 | 2019-2025 | |
| Abbott Laboratories | $43.48 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $39.12 | 2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $24.41 | 2025 | |
| Astellas Pharma US INC | $20.36 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.19 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.91 | 2020 | |
| Merck Sharp & Dohme LLC | $16.19 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Rupcich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.